Ipsen Manufacturing
Ipsen is a biotechnological group aiming to become a leader in specialty healthcare solutions for debilitating diseases. Its strategy is supported by three franchises, neurology, endocrinology and urology-oncology.
Ipsen has a growing portfolio in prostate cancer, bladder cancer or neuro-endocrine tumours and a presence in primary care.
The group has more than 4,500 employees spread across R&D and manufacturing sites located in China, France, Ireland, the UK and the US.
Financial Data
-
31st Dec 17 Source: CRO
- €122.2 million turnover
-
€104 million
profit - 125 employees
-
31st Dec 16 Source: CRO
- €103 million turnover
-
€85.7 million
profit - 111 employees
- 5 more years available »
Ranking
By Turnover
(€122.2 million)- 430th in Top Companies
- 47th in Health
- 42nd in Pharma
- 63rd in Manufacturing
By Employees
(125)- 676th in Top Companies
- 81st in Health
- 62nd in Pharma
- 101st in Manufacturing
- 125
- €122.2 million
Employees
- James Byrne General Manager
Latest News
- Feb 22 Billionaire Zara founder and German funds vie for prime Dublin offices
- Feb 22 Google completes purchase of Treasury Building for €120m
- Feb 22 Garda mobile contract win causes concern over Eir’s use of Huawei kit
- Feb 22 Communicorp says ban on Currency journalists strictly business
- Feb 22 AIB lines up former HSBC executive McDonagh as chairman